Bruker

BRKR

Market cap $4.87B

Overview Fund Activity

32.11 USD

-1.15

3.46%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

32.11

0.00

0%

1 day

-3.46%

5 days

5.21%

1 month

-6.22%

3 months

-14.65%

6 months

-31.59%

Year to date

-45.4%

1 year

-50.62%

5 years

-17.75%

10 years

74.89%

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Employees: 11,396

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 155 | Existing positions reduced: 123

2.6% more ownership

Funds ownership: 79.45% [Q1] → 82.05% (+2.6%) [Q2]

2% more capital invested

Capital invested by funds: $5.03B [Q1] → $5.12B (+$92.8M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]

8% less funds holding

Funds holding: 397 [Q1] → 366 (-31) [Q2]

33% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 80

65% less call options, than puts

Call options by funds: $11.7M | Put options by funds: $33.7M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

18% upside

Avg. target

$44

38% upside

High target

$50

56% upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

Wells Fargo Brandon Couillard	$50	Overweight Maintained	5 Aug 2025
Stifel Daniel Arias	$40	Hold Maintained	5 Aug 2025
Citigroup Patrick Donnelly	$38	Neutral Maintained	4 Aug 2025
Barclays Luke Sergott	$43	Overweight Maintained	4 Aug 2025
B of A Securities Derik De Bruin	$50	Buy Maintained	26 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about BRKR published over the past 30 days

BRUKP: Bruker Corp 6.375% Mandatory Convertible Preferred Stock IPO

Bruker Corporation 6.375 PREF SER A is a new 6.375% mandatory convertible preferred stock from Bruker, offering fixed income but closely tied to BRKR's common stock performance. Bruker's fundamentals have weakened, with declining performance and a dividend cushion that's thinner than ideal for preferred holders. Option-adjusted yield to maturity is unappealing versus peer term preferreds of comparable maturity, especially given the lack of 1940 Act protections.

BRUKP: Bruker Corp 6.375% Mandatory Convertible Preferred Stock IPO

The Motley Fool

Why Bruker Stock Tumbled by Almost 12% Wednesday

Medical device and diagnostics company Bruker (BRKR -11.68%) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market, leaving it with a nearly 12% price decline on the session.

Why Bruker Stock Tumbled by Almost 12% Wednesday

Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker has granted the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock. The offering is expected to close on or about September 8.

Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

Zacks Investment Research

Bruker (BRKR) Up 3.6% Since Last Earnings Report: Can It Continue?

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

Bruker (BRKR) Up 3.6% Since Last Earnings Report: Can It Continue?

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday.

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of Mandatory Convertible Preferred Stock, solely to cover over-allotments, if any.

Bruker Announces Public Offering of $600 Million of Mandatory Convertible Preferred Stock

‘Big Short' Michael Burry stock portfolio update

Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.

‘Big Short' Michael Burry stock portfolio update

Bruker: Former Academia Customer Strength, Now Incredible Weakness

Bruker faces significant headwinds due to NIH funding cuts, heavy reliance on academia, and declining financial performance versus peers. Despite operational challenges and a sharp drop in valuation, Bruker's NMR technology moat and long-term potential remain intact. I'm accumulating shares gradually at these low valuations, confident in mean reversion and management's ability to consolidate acquisitions.

Bruker: Former Academia Customer Strength, Now Incredible Weakness

Bruker Announces Quarterly Dividend

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop.

Bruker Announces Quarterly Dividend

Zacks Investment Research

Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract

BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.

Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract

See News Rankings

Charts implemented using Lightweight Charts™